Procter & Gamble Health Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹382 Cr +17.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY18.
P&

Procter & Gamble Health Ltd

Q4 FY18Pharmaceuticals & Biotechnology

Procter & Gamble Health Q4 FY18 earnings call: Revenue & Margins

Q4 FY18 investor presentation: what the company reported on revenue, margins and capex.

Based on Procter & Gamble Health Ltd's Q4 FY18 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹5,416
Market cap₹9.1K Cr
P/E27.4

The short version

The investor presentation reports the following quarterly financial figures and changes: - EBITDA: INR 23.5 million, up 13% year-on-year.

From Procter & Gamble Health Ltd's Q4 FY18 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

Summary of relevant financial figures related to the Proposed Transaction: - BPL Business revenue (FY ended 31 Dec 2017): INR 3,734 million (35% of total company revenue) - BPL Business normalized EBITDA (FY ended 31 Dec 2017): INR 515 million (28% of total normalized EBITDA) - Consideration for Proposed Transaction: INR 10,520 million

2 more points from Procter & Gamble Health Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Procter & Gamble Health Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It discusses valuation, consideration, fairness opinions, business strategy post-transaction, ancillary commercial arrangements, and related approvals. There is no reference to order-related metrics in the extracted text.

Procter & Gamble Health Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹382 Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Procter & Gamble Health Ltd Q4 FY18 results?

The investor presentation reports the following quarterly financial figures and changes: - EBITDA: INR 23.5 million, up 13% year-on-year.

What is Procter & Gamble Health Ltd share price analysis?

Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.